Fig. 4

ABT-263/navitoclax enhances ABBV-321 treatment responses in vivo. HCI-010 (Supplemental Figure 1c) or HCI-025 (Supplemental Figure 1d) tumors were treated with vehicles, ABT-263, ABBV-321, ABT-263+ABBV-321, AB095-PBD, or ABT-263+AB095-PBD. The graphs present tumor growth as a percent of pre-treatment tumor volumes for each tumor (n = 2–5 per group) enrolled in one of two independent treatment studies (e.g., blue, study A; red, study B). Each symbol represents a tumor. Each line represents the grand mean. For HCI-010 (a), note the tumor volume reductions and regressions observed under ABT-263 treatment, and unlike ABT-414, under ABBV-321 treatment. Note the dramatic regressions observed following ABBV-321 are further enhanced by ABT-263 combined treatments. p values < 0.05 (*) and p values < 0.01 (**) are indicated for the most relevant comparisons (Welch’s one-tailed test: ABBV-321 versus ABT-263+ABBV-321 and ABT-263+ABBV-321 versus ABT-263+AB095-PBD). For HCI-025 (c) tumors, note the tumor volume reductions and regressions following ABBV-321 and enhanced responses following combined treatment with ABT-263. p values < 0.001 (***) and p values < 0.0001 (****) are indicated for the most relevant comparisons (Welch’s one-tailed test: ABBV-321 versus ABT-263+ABBV-321 and ABT-263+ABBV-321 versus ABT-263+AB095-PBD). p values, determined by Welch’s one-tailed test, for HCI-010 and HCI-025 vehicles versus ABT-263, ABBV-321, ABT-263+ABBV-321, AB095-PBD, and ABT-263+AB095-PBD are presented in Supplemental Table 2c. Representative H&E images for HCI-010 (b) or HCI-025 (d) tumors, corresponding to each treatment group, are shown to highlight pathological responses associated with ABBV-321 and ABT-263 treatments. Note that near-complete pathological responses were achieved following ABT-263+ABBV-321 combined treatments of HCI-010 tumors. The H&E are presented as matched low- and high-magnification images. Scale bar, ~ 200 μm